Financial Avengers Inc. Boosts Stock Holdings in Pfizer Inc. $PFE

Financial Avengers Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 19.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 89,792 shares of the biopharmaceutical company’s stock after purchasing an additional 14,524 shares during the period. Pfizer comprises about 1.0% of Financial Avengers Inc.’s holdings, making the stock its 19th largest holding. Financial Avengers Inc.’s holdings in Pfizer were worth $2,177,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of PFE. Vanguard Group Inc. grew its position in shares of Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares in the last quarter. Geode Capital Management LLC lifted its stake in Pfizer by 1.4% in the second quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after acquiring an additional 1,820,634 shares during the last quarter. Northern Trust Corp increased its position in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock valued at $1,579,340,000 after purchasing an additional 3,943,397 shares during the last quarter. Amundi raised its holdings in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 2.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock worth $1,191,760,000 after purchasing an additional 1,135,457 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PFE. Morgan Stanley decreased their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Guggenheim upped their price objective on shares of Pfizer from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.39.

Pfizer Trading Down 0.0%

NYSE:PFE opened at $25.72 on Thursday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock’s 50 day simple moving average is $24.94 and its 200-day simple moving average is $24.55. The firm has a market cap of $146.21 billion, a P/E ratio of 13.68, a PEG ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.